WEBINAR

Molecular DNA and RNA Profiling
in the Management of Patients
with Solid Tumors

.scrollsequence-wrap {height:initial!important;} .scrollsequence-pages-wrap {height:initial} .scrollsequence-page {position:relative;opacity:initial;display:block ;visibility:initial}

SAVE THE DATE

Thursday, September 26, 2-3 p.m. ET

During the educational session, learn about:

The clinical role of DNA and RNA profiling inprecision oncology

Which tests to order and when

Various molecular abnormalities in solid tumors

Targeted and immune therapeutic relevance ofdetecting molecular abnormalities

How to use molecular profiling in evidence-basedtreatment decisions

When to use liquid biopsy vs. tissue biopsy profiling

Specific tests included in the webinar discussion include:

Solid Tumor Profile 434 gene (DNA)

Solid Tumor Fusion / Expression Profile60+ gene (RNA)

NTRK 1/2/3

Presenter:

Maher Albitar, M.D.
CEO/CMO, Founder
Genomic Testing Cooperative

Moderated by:

Steve Kargas, M.D., Ph.D., MBA
Director, Surgical Pathology
CSI Laboratories

We are marketing specialists, designers, developers and entrepreneurs that are dedicated to create digital solutions to every of your branding needs, including PR, content marketing and social media solutions.

WEBINAR

Molecular DNA and RNA Profiling in the Management of Patients with Solid Tumors

Thursday, September 26, 2-3 p.m. ET

Thursday, September 26, 2-3 p.m. ET

Specific tests included in the webinar discussion include:

Presenter:

Moderated by:

Molecular DNA and RNA Profiling
in the Management of Patients
with Solid Tumors